Novotech Partners with South Korea’s Pusan National University Hospital

June 18, 2020

Novotech, the leading Asia-Pacific biotech specialist CRO, has partnered with South Korea’s world-class Pusan National University Hospital (PNUH).

Novotech notes the Partnership is designed to further support Novotech’s biotech clients run their clinical trials in the region.

Dr. Jeong Zoo Lee, the President of PNUH, said: “The PNUH site team and Novotech have worked together on a number of studies already. We have progressed to a formal agreement to support Novotech’s biotech clients across all clinical research and patient recruitment areas.

“We are pleased to partner with a regional CRO leader with such an outstanding reputation internationally,” said Dr. Lee.

Dr. Yooni Kim, Executive Director, Asia Operations said: “Novotech was very pleased to establish a Partnership with PNUH, which has completed more than 340 clinical trials and is ranked 7th in terms of number of clinical trials in South Korea *GlobalData.

“The PNUH site offers biotechs quality infrastructure, world-class medical and hospital facilities, as well as South Korea’s supportive rapid start-up environment. The main therapeutic areas at PNUH have been oncology, infectious disease, cardiovascular and gastrointestinal,” said Dr. Kim.

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to deliver unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

SourceNovotech
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version